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Purpose: Evidence suggests that circulating serum microRNAs (miRNAs) might preferentially 
target immune-related mRNAs. If this were the case, we hypothesized that immune-related 
mRNAs would have more predicted serum miRNA binding sites than other mRNAs and, 
reciprocally, that serum miRNAs would have more immune-related mRNA targets than non-
serum miRNAs.
Materials and methods: We developed a consensus target predictor using the random for-
est framework and calculated the number of predicted miRNA–mRNA interactions in various 
subsets of miRNAs (serum, non-serum) and mRNAs (immune related, nonimmune related).
Results: Immune-related mRNAs were predicted to be targeted by serum miRNA more than 
other mRNAs. Moreover, serum miRNAs were predicted to target many more immune-related 
mRNA targets than non-serum miRNAs; however, these two biases in immune-related mRNAs 
and serum miRNAs appear to be completely independent.
Conclusion: Immune-related mRNAs have more miRNA binding sites in general, not just for 
serum miRNAs; likewise, serum miRNAs target many more mRNAs than non-serum miRNAs 
overall, regardless of whether they are immune related or not. Nevertheless, these two independent 
phenomena result in a significantly larger number of predicted serum miRNA–immune mRNA 
interactions than would be expected by chance.
Keywords: biomarker, posttranscriptional regulation, random forest, target prediction
Introduction
MicroRNAs (miRNAs) are small (~21 nucleotides long) noncoding RNAs that func-
tion as posttranscriptional regulators of gene expression in metazoans and plants.1 The 
identification of stable circulating miRNAs in mammals within a wide range of bodily 
fluids, including serum, suggested their use as noninvasive biomarkers.2 Indeed serum 
miRNA levels have been observed to correlate with a number of diseases, including 
various cancers, which has attracted great interest for their use for cancer diagnosis 
and to predict prognosis and response to therapy.3
Both the cellular origin and biological function of extracellular miRNAs remain 
controversial.4 Evidence exists for both passive release of miRNA from cells during cell 
death and cell–cell signaling, especially by circulating miRNAs encapsulated within 
apoptotic bodies or exosomes.5,6 Interestingly, blood cell counts significantly influence 
plasma miRNA biomarker levels, and many reported miRNA cancer biomarkers are 
in fact highly expressed in blood cells, suggesting that the levels of some circulating 
serum miRNAs are by-products of immune cell function.5 Regardless of the precise 
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origins of circulating serum miRNAs, their known correla-
tion with disease states, along with their co-localization with 
circulating immune cells, suggests that they represent a rich 
source of information about the status of the immune system. 
Consistently, a number of miRNAs have been shown to have 
critical roles in the regulation and development of adaptive 
and innate immune cells.7
A more mechanistic understanding of circulating 
 miRNAs in the regulation of immune cell responses and 
development would enhance their use as disease biomarkers.8 
One critical step in this direction is to associate circulating 
miRNAs with specific mRNA targets. Experimental iden-
tification of miRNA–mRNA interactions has been carried 
out using both small- and large-scale methods. Small-scale 
methods generally involve perturbing the expression level of 
a single miRNA of interest in a cell line or a tissue, following 
expression changes in putative targets and finally confirming 
the interaction physically.9 Recently, cross-linking immu-
noprecipitation (CLIP)-based techniques have been applied 
to miRNA–mRNA detection (high-throughput sequenc-
ing of RNA isolated by crosslinking immunoprecipitation 
[HITS-CLIP] and photoactivatable ribonucleoside-enhanced 
crosslinking and immunoprecipitation [PAR-CLIP]), 
greatly expanding the scope of putative miRNA–mRNA 
interactions.10,11 Computational miRNA–mRNA prediction 
integrates experimentally observed interactions along with 
sequence-level complementarity, conservation and other fea-
tures.12 The use of both small-scale and large-scale datasets 
to train and test miRNA–mRNA target prediction remains 
challenging due to differences in the precision of various 
experimental approaches.
A 2008 study that used a simple consensus-based predic-
tor found that the 3′-untranslated regions (UTRs) of immune-
related genes had more predicted miRNA binding sites than 
background genes.13 This study did not distinguish between 
circulating and noncirculating miRNAs. We speculated that 
circulating serum miRNAs (referred to here as serum miR-
NAs) preferentially target genes expressed highly in immune 
cells. Specifically, we hypothesized that immune-related 
mRNAs would have more predicted serum miRNA binding 
sites than other mRNAs and, reciprocally, that serum miRNAs 
would have more predicted immune-related mRNA targets 
than non-serum miRNAs.
To test our hypotheses, we developed a consensus predic-
tor using the random forest (RF) framework and carefully 
trained it on data from both validated small-scale miRNA–
mRNA interaction experiments and recent large-scale data 
for both human and mouse miRNAs. We monitored the 
amount of large-scale data in order to identify an optimal 
balance between the two data sources. The results were highly 
consistent between human beings and mice in spite of the 
fact that independent data sources were utilized. Interest-
ingly, although we found that immune-related mRNAs were 
predicted to be targeted by serum miRNAs modestly more 
than other mRNAs and that serum miRNAs were predicted 
to target many more immune-related mRNA targets than non-
serum miRNAs, the two phenomena are, in fact, independent. 
That is, immune-related mRNAs have more miRNA binding 
sites in general, not just for serum miRNAs; reciprocally, 
serum miRNAs target many more mRNAs in general, not 
just immune-related mRNAs. In spite of this independence, 
the combined miRNA and mRNA biases result in a much 
greater number of serum miRNA–immune mRNA interac-
tions than expected by chance.
Materials and methods
Sequence data sources
All human and mouse miRNAs were taken from miRBase 
(v21).14 Human and mouse mRNAs were retrieved from the 
Ensembl database.15 If the Ensemble mRNAs transcripts could 
be associated with established microarray experiments, they 
were used for further study.16,17 This mapping resulted in 22,084 
and 23,575 mRNAs in human beings and mice, respectively.
Immune-related mRNAs
Immune-related mRNAs in human beings were taken from 
the microarray-based immune response in silico dataset.16 
This dataset consists of human mRNAs for which signifi-
cantly higher expression was observed in any of six immune 
cell types (T-cell, B-cell, natural killer cell, monocyte, den-
dritic cell and neutrophil) than in a representative set of non-
immune cells (brain, lung and kidney cells).16 Immune-related 
mRNAs in a mouse consisted of 1,227 orthologous mRNAs 
that had immune cell lineage-specific expression signatures 
in both human beings and mice.18 All mRNA names were 
mapped to the latest version of Ensembl, and only those with 
unambiguous gene names and annotations were retained for 
further analysis, resulting in 1,632 and 1,221 immune-related 
mRNAs in human beings and mice, respectively.
Circulating miRNAs
A set of 93 circulating miRNAs were taken from a previous 
study that demonstrated consistent expression levels in the 
serum of a large group of healthy donors.2 A set of 96 mouse 
serum miRNAs was assembled from two previous studies.19,20 
Nomenclature of both human and mouse miRNAs was cor-
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Serum miRNAs that target immune-related mRNAs
miRNA–mRNA interactions
A set of 777 high-confidence, experimentally validated 
small-scale miRNA–mRNA interactions was extracted from 
miRecords.9 A subset of large-scale (HITS-CLIP and PAR-
CLIP) interactions was taken from DIANA-TarBase v7.21 The 
large-scale interactions were sorted by the number of times 
each interaction was observed in an independent experi-
ment. The selection of how many large-scale interactions to 
use was based on the performance of the consensus-based 
predictor, as described in the following. In brief, the large-
scale interactions were added to the small-scale interactions 
incrementally and were used for training and testing the 
consensus-based predictor and for testing each individual 
predictor, as described in the following.
Computational miRNA–mRNA 
target prediction
Individual target predictors used in this study included 
 TargetScan, DIANA-microT-CDS, miRDB and miRanda.22–25 
The choice of target predictors was based on the fact that, 
collectively, these predictors cover most features used in 
miRNA–mRNA target prediction and that they are regularly 
updated.26,27
We developed a consensus predictor based on the output 
of these four independent target predictors. Our consensus 
prediction method utilized the RF framework as implemented 
in the RandomForestClassifier class in the sklearn.ensemble 
package of the Python programming language. Raw outputs 
of the four individual predictors differed in scale and sign. 
For the TargetScan predictions, we used the context score 
of predicted miRNA–mRNA interactions.28 For DIANA-
microT-CDS, the miTG score was used.24 For MiRanda, the 
mirSVR score was used after reversing the sign.22 Each score 
was scaled between 0 and 1 using min–max normalization.
In addition to the scores, the consensus method utilized 
the minimum distance between binding locations as a feature, 
the logic being that predictions with a smaller spread in dis-
tances would be more reliable. All training was carried out 
using the Matthews correlation coefficient (MCC) as a target 
function with the experimental miRNA–mRNA interactions 
randomly divided into 80% training and 20% test data. For 
estimating the number of trees (n_estimators) and maximum 
tree depth (n_ features), threefold cross-validation was used 
while searching a grid of values in the 5–100 and 1–20 range 
using a fixed set of 1,277 large-scale interactions and 777 
small-scale interactions. Optimal values of 46 and 3 were 
subsequently obtained for the number of trees and maximum 
tree depth, respectively.
Further training of the consensus-based predictor 
involved adjusting the number of large-scale interactions 
based on the performance of the consensus predictor. We 
iteratively added the large-scale interactions to the 777 manu-
ally curated interactions in steps of 100 interactions. At each 
step, we examined the MCC from each individual predictor 
and our meta-predictor. The experimental data were again 
randomly split into training (80%) and test (20%) sets, as 
mentioned earlier. We artificially kept the class imbalance 
constant by repeated random sampling negative examples. To 
limit noise from random sampling and splitting, we repeated 
this operation 10 times for each dataset size.
Results and discussion
Consensus target prediction shows stable 
improvement over individual predictors
We evaluated four target prediction methods (DIANA-
microT-CDS, TargetScan, miRDB and miRanda) and the 
consensus method, while adjusting the number of large-scale 
interactions used. First, we sorted the large-scale experimen-
tal data by the frequency that the interaction was observed in 
independent experiments. Next, we iteratively added these 
sorted interactions to 777 manually curated interactions, 100 
interactions at a time. At each step, we computed the MCC 
for each individual predictor and the consensus predictor. 
We repeated this retraining 10 times for each dataset size.
Figure 1 shows the MCC of the consensus method along 
with the individual methods for the first 10 steps, where the 
x-axis shows the size of the large-scale data portion. As the 
figure shows, the mean MCC value of the consensus method 
was consistently above that of the individual predictors. This 
relative performance was maintained even when the dataset 
was dominated by the large-scale data (Figure S1A–D). The 
consensus MCC value reached a peak of 0.45 at the fifth 
step (red dashed line), indicating addition of 500 large-scale 
interactions. As the small-scale/large-scale balance shifted 
more toward large-scale data, the performance of all pre-
dictors, including the consensus-based predictor, declined, 
suggesting that the large-scale data are either noisy or that 
the features used in the predictors were insufficient to learn 
from the additional data. The consensus-based method con-
sistently achieved a higher overall MCC value (0.37) than 
any of the individual predictors (0.33, 0.30, 0.33 and 0.21 
for DIANA-microT-CDS, TargetScan, miRDB and miRanda, 
respectively). For these reasons, we used the consensus pre-
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Serum miRNAs exhibit apparent 
preference for immune-related mRNAs
We next examined the number of miRNA–mRNA interac-
tions for different subsets of miRNAs (serum, non-serum) 
and mRNAs (immune, nonimmune). We observed a modest 
but statistically significant (median values 3 and 4, Mann–
Whitney U test: p-value 1.76E - 18) increase in the number 
of interactions for immune-related human mRNAs with 
serum miRNAs compared to nonimmune-related mRNAs, as 
shown in Figure 2A. Moreover, a similar trend was observed 
for mouse immune-related mRNAs ( Figure S2A), which is 
consistent with previous observations that immune-related 
mRNAs have more miRNA binding sites than nonimmune-
related mRNAs.13 Next, we examined the reciprocal 
 relationship and analyzed the number of immune-related 
mRNAs targeted by serum and non-serum miRNAs. As 
shown in Figure 2B, serum miRNAs target many more 
immune-related mRNAs than non-serum miRNAs (median 
values 34 and 79, Mann–Whitney U test: p-value 2.89E - 30). 
The difference is particularly pronounced for miRNAs that 
have few or no predicted targets, but is maintained across the 
entire distribution of hits. Again, a similar trend was observed 
in mouse (Figure S2B). Taken together, these results appear 
to support the contention that serum miRNAs preferentially 
target immune-related mRNAs.
Serum miRNA and immune-related 
mRNA preferences are independent
We can see from Figure 2 that the bias in the serum versus non-
serum miRNA (Figure 2B) is greater than that of immune versus 
related nonimmune mRNAs (Figure 2A), suggesting that the 
driving forces for the two phenomena might be different. More-
over, in order to say that serum miRNAs prefer immune-related 
mRNAs, it is necessary to show that the bias in Figure 2A is not 
observed for non-serum miRNAs. However, in contrast to our 
expectations, we found nearly the same modest but statistically 
significant (median values 40 and 50, Mann–Whitney U test: 
p-value 3.89E - 18) increase in the number of immune-related 
interactions for non-serum miRNAs, as shown in Figure 3A. 
Symmetrically, the dramatic differences between serum and 
non-serum miRNAs in targeting immune mRNAs (Figure 2B) 
were also observed for nonimmune mRNAs (median values 333 
and 672, Mann–Whitney U test: p-value 2.32E - 30), as shown 
in Figure 3B and in Figure S3 for mouse. In other words, the 
Figure 1 Performance of the predictors based on large-scale data.
Note: The red dashed line indicates the dataset size for which the RF-based 
consensus method achieved the maximum MCC.
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Figure 2 Serum miRNAs apparently prefer immune-related mRNAs.
Notes: (A) The distribution of immune and nonimmune mRNAs based on the number of serum miRNAs predicted to target. Each bin represents the frequency (in 
percentage) of immune (red) and nonimmune (blue) mRNAs (y-axis) targeted by a similar number of serum miRNAs (x-axis). (B) Distribution of serum and non-serum 
miRNAs based on the number of immune-related target mRNAs. Each bin corresponds to the percentage of serum (red) and non-serum miRNAs (blue) that target the same 
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Serum miRNAs that target immune-related mRNAs
3′-UTRs of immune-related mRNAs simply have more miRNA 
binding sites than other mRNAs, as previously reported,13 
and serum miRNAs have many more targets than non-serum 
miRNAs, regardless of whether the targets are immune related 
or not. Independently, these two phenomena lead to a greater 
number of circulating miRNA–immune mRNA interactions 
than would be expected by chance, as shown in Table 1 for 
human beings and in Table S2 for mice. For example, all 93 
serum miRNAs and 1,632 immune-related mRNAs in human 
beings might be expected to have (93/2,613) × (1632/22,084) = 
0.0026 interactions by chance. However, almost threefold more 
interactions were observed based on the consensus method, that 
is, 7,041/904,296 = 0.0078 interactions (Table S1). In contrast, 
the expected number of interactions between noncirculating 
miRNAs (2,613 - 93 = 2,520) and nonimmune-related mRNAs 
(22,084 - 1,632 = 20,452) would be (2,520/2,613) × (20,452/22
,084) = 0.89, but the observed value was 75,732/904,296 = 0.83 
interactions (Table S1).
The basis for the observed preferences in immune-related 
3′-UTRs may be due to several factors. For example, it is 
already well known that immune mRNAs, especially their 
3′-UTRs, contain more adenylate-uridylate (AU)-rich ele-
ments.29 Asirvatham et al13 found that AU-rich regions in 
immune-related mRNAs were frequently targeted by miR-
NAs. In addition to their nucleotide composition, shorter tran-
scripts tend to be less susceptible to regulation by miRNAs 
due to loss of miRNA binding sites.7 Indeed, the background 
distribution of 3′-UTR length has a median value of 1,350 nt 
in human beings, whereas the value for immune-related genes 
is 1,676 nt, which is statistically significant (Mann–Whitney 
U test: p = 5.60E - 18; Figure S4). Therefore, the results in 
Figures 2A and 3A can be rationalized in terms of the length 
of the 3′-UTRs in immune-related mRNAs. Taken together, 
immune-related mRNAs have a larger than expected number 
of miRNA binding sites, but are not specifically biased toward 
circulating miRNAs.
It is currently unclear why serum miRNAs would have 
dramatically more predicted targets than non-serum miRNAs. 
Since serum levels of some miRNAs are known to correlate 
with cellular miRNA levels, their presence in the blood 
might reflect higher expression levels overall.4 It has also 
been reported that nucleotide content affects serum miRNA 
extraction efficiency.30 At the same time, the ability to bind 
more mRNA targets might result from a sequence bias in the 
serum miRNAs. To test this idea, we surveyed the nucleo-
tide content in serum miRNAs and found that, indeed, there 
were statistically significant differences in nucleotide usage 
between serum and non-serum miRNAs. Adenine (A) was 
more frequent and cytosine (C) was less frequent in serum 
miRNAs than in non-serum miRNAs; in non-serum miRNAs, 
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Figure 3 Serum miRNA and immune-related mRNA preferences are independent.
Notes: (A) The distribution of immune and nonimmune mRNAs based on the number of non-serum miRNAs predicted to target. Each bin shows the frequency (in 
percentage) of immune (red) and nonimmune (blue) mRNAs (y-axis) targeted by a similar number of non-serum miRNAs (x-axis). (B) Distribution of serum and non-serum 
miRNAs based on the number of nonimmune target mRNAs. Each bin corresponds to the percentage of serum (red) and non-serum miRNAs (blue) that target the same 
number of nonimmune mRNAs (x-axis).
Abbreviation: miRNA, microRNA.
Table 1 Predicted miRNA–mRNA interactions in human beings
miRNAs mRNAs Observed Expected Ratio
Non-serum Nonimmune 0.83 0.89 0.93
Immune 0.096 0.071 1.35
Serum Nonimmune 0.066 0.033 1.98
Immune 0.0078 0.0026 2.93
Notes: Observed and expected frequencies of miRNA–mRNA interactions are 
shown. Observed values were calculated by the consensus method’s genome wide 
predictions. The expected values were calculated by considering the frequencies of 
all subsets of miRNAs and mRNAs in this study. As the ratio increases, the green 
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usage of serum and non-serum miRNAs is shown in Table 2 
and Figure 4. Very similar results were observed for serum 
and non-serum miRNAs in mouse, with the exception that 
uracil (U) was the most frequent nucleotide in serum miRNAs 
(Table S3 and Figure S5).
Next, we examined the position-wise nucleotide fre-
quency of both serum and non-serum miRNAs to see if there 
is any difference in a particular nucleotide usage at any given 
position in the miRNA sequences. The results show that 
serum miRNAs tend to start with U at position 1 in signifi-
cantly high frequency compared to non-serum miRNAs in 
human beings (Figure S6). The least frequent nucleotide for 
serum miRNAs at position 1 was G. The frequency of U is 
also significantly different in serum miRNAs at positions 9, 
17, 21 and 22. Serum miRNAs also have significantly high 
frequencies of nucleotide A at positions 2, 4. 5, 7, 8, 13, 15, 
16, 18 and 22. This comprises almost half (~45%) of miRNA 
sequences considered, and this is consistent with Figure 4. 
However, we rarely see any positions where serum miRNAs 
have remarkable high frequencies of C and G, except the 
positions 19 and 20 where G has significantly high frequency 
in serum miRNA sequences. Interestingly, we observed com-
parable position-wise nucleotide frequencies for mouse too, 
although there were a few positions for which mouse serum 
miRNAs have different nucleotide compositions (Figure S7). 
The seed region (positions 1–8) of miRNAs is the most 
important feature of miRNA–target mRNA biding, and we 
can see some notable differences in serum miRNAs and non-
serum miRNAs in that region. For example, the seed region 
in human serum miRNAs most likely starts (position 1) and 
ends (position 9) by U. Next, the most frequent nucleotide at 
positions 2, 4, 7 and 8 is A. Position 5 is likely to be A or G. 
In our results, positions 3 and 6 of the seed region did not 
show preference to any nucleotide. Based on these results in 
human beings and mouse, the consensus seed sequence for 
human serum miRNAs would be UANA(A/G)NAA flanked 
by U, and for mouse serum miRNAs, it would be UAAN(A/G)
NNN flanked by U.
The nucleotide usage suggests that there are fundamental 
differences between serum and non-serum miRNAs that can 
be understood at the sequence level; however, the detailed 
nature of these differences remains to be clarified.
Biological consistency of 
miRNA-targeting patterns
It is well known that miRNA–mRNA target prediction algo-
rithms suffer from false positive and false negative predic-
tions. In spite of the use of consensus-based prediction, which 
apparently mitigates such errors to some extent, it is useful 
to have a qualitative overview of the results presented here. 
To this end, we made use of human cell type-specific gene 
Table 2 Nucleotide frequency of human miRNAs
NT Serum miRNAs Non-serum miRNAs p-value
A 0.283 0.219 1.69E - 09
G 0.243 0.290 0.00088
C 0.198 0.236 0.0042
U 0.275 0.256 0.071
Notes: The second and third columns are the mean frequencies of A, G, C and 
U nucleotides for serum and non-serum miRNAs. Green color indicates most 
frequent nucleotides, while light blue color shows less frequent nucleotides. Two-
tailed p-values for serum nucleotides were calculated from the ratio distributions of 
similar number of randomly selected miRNAs (10,000 times).
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Figure 4 Nucleotide distributions of serum (A) and non-serum (B) miRNAs in human beings.
Notes: Nucleotide frequencies (expressed as a ratio to other nucleotides) of serum and non-serum miRNAs were calculated. Then, the frequency distribution of each 
nucleotide was constructed for serum and non-serum miRNAs.
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Serum miRNAs that target immune-related mRNAs
expression data to characterize mRNA binding profiles of 
each circulating miRNA in human beings. For each miRNA, 
to indicate its specificity to particular immune cell types, we 
counted the number of predicted interactions with mRNAs 
specifically expressed in each cell type, as defined in Abbas 
et al.16 Then, based on these mRNA binding profiles, we 
clustered the circulating miRNAs to compare with known 
lineage relationships (Figure 5).
Since dendritic cells, monocytes and neutrophils are 
all thought to descend from the myeloid lineage, we would 
expect to see higher similarity among these cells than, for 
example, B, T and natural killer cells, which descend from 
the lymphoid lineage. Figure 5 shows that such similarity is 
indeed recapitulated and that B and T cells contain mRNAs 
with similar miRNA binding profiles. In addition, we observe 
populations of miRNAs specifically targeting B or T cells. 
Similarly, we observed several clusters of miRNAs that 
appear to target mRNAs that are not present in cells from 
the lymphoid lineage. Such qualitative grouping is reassur-
ing as it suggests that the differences observed in this study 
reflect biological differences and are not simply an artifact of 
the underlying prediction methods. Moreover, the ability to 
interpret predicted miRNA–mRNA interactions functionally 
is critical if serum miRNA levels are to be used as biomark-
ers of disease.
Conclusion
Serum miRNAs are potentially attractive as biomarkers but 
their cellular origins as well their biological functions are 
largely unknown. In the last decade, a number of miRNAs 
Figure 5 A heat map of serum miRNAs targeting immune-related genes specifically expressed in the human immune cells.
Notes: Colors represent Z-score of the number of predicted interactions with mRNAs specifically expressed in each cell type. Each row corresponds to a human serum 
miRNA. Serum miRNAs were hierarchically clustered by the number of immune-related genes they target in each immune cells (in columns).
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with functional roles in the immune system have been 
described.31–34 The majority of such studies were carried 
out by knocking out or overexpressing miRNAs of inter-
est and then observing the changes in gene expression 
levels in particular immune cells. Here, we took a differ-
ent approach: we prioritized miRNA–mRNA pairs with 
consensus target predictions and looked for target mRNAs 
with high expression in immune cells. We discovered that 
serum miRNAs target immune-related mRNAs much more 
than noncirculating miRNAs but that this difference is 
mostly due to two independent phenomena: 1) circulating 
miRNAs tend to target many more mRNAs in general and 2) 
immune-related mRNAs tend to be targeted slightly more, 
in general, than nonimmune-related mRNAs. Indeed, we 
can see these two effects independently, if we compare all 
pairs of expected and observed miRNA–mRNA interaction 
frequencies (Table 1).
There are several directions for future work to further 
elucidate the role of miRNA in immune cell regulation. The 
categorization of miRNAs into two groups – serum and non-
serum – is only a first-order approximation. Serum miRNAs 
can be further subdivided according to their specific source 
(plasma or serum) or type of compartmentalization – e.g., 
those bound by the Argonaute 2 (AGO2) protein encapsu-
lated in apoptotic bodies or in exosomes.4,35 Similarly, the 
categorization of mRNAs into immune/nonimmune-related 
mRNAs should take into account both up- and downregulated 
genes as well as additional cell types such as macrophages 
and innate lymphoid cells. Moreover, in the future, we aim 
to subdivide nonimmune cells into endothelial or stromal 
cells and to specifically examine expression in lymph nodes, 
spleen and bone marrow.
Despite these simplifications, the data presented in this 
study are remarkably consistent between human beings and 
mouse. The fact that serum miRNA–immune-related mRNA 
interactions are predicted to occur at higher frequencies than 
expected by chance, along with their co-localization in blood, 
strongly suggests that serum miRNAs carry important infor-
mation about immune cell function. Consistently, the reca-
pitulation of myeloid and lymphoid lineages from predicted 
interaction profiles suggests that groups of miRNAs in the 
blood can collectively be associated with the status of basic 
immune cell groups. Considering the fact that immune cell 
sequencing is also emerging as a very sensitive and specific 
biomarker for cancer, the combination of miRNA and mRNA 
levels in the blood represents the next-generation RNA-based 
disease diagnostics.36 In order to facilitate further use of 
specific miRNAs as biomarkers of immune status, we have 
summarized the number of immune-related targets for each 
miRNA utilized in this study in Table S3.
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